TSUCHIYA Ken
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Professor (Fixed Term)
Article types Original article
Language English
Peer review Non peer reviewed
Title [Bone disease in the field of CKD-MBD].
Journal Formal name:Clinical calcium
Abbreviation:Clin Calcium
ISSN code:(0917-5857)0917-5857(Linking)
Volume, Issue, Page 26(6),pp.875-80
Author and coauthor Yajima Aiji, Tsuchiya Ken, Yokota Hiroki, Nitta Kosaku
Authorship 2nd author
Publication date 2016/06
Summary The pathophysiology and treatment for renal bone disease have made remakable progress. Moreover, osteocyte reseach has made tremendous progress. In the clinical aspect, (1) hyperphosphatemia, (2) hyperparathyroid and hypoparathyroid bone disease in patients with chronic kidney disease, (3) increased serum level of fibroblast growth factor 23 (FGF-23) and(4) reduced level of Klotho should be taken into consideration when analyzing these conditions. On the other hand, hyperphosphatemia must be successfully treated. Hyperparathyroid bone disease has been successfully treated with vitamin D sterol, cinacalcet hydrochloride and parathyroidectomy, however, the treatment of hypoparathyroidism inpatient with diabetes or non-diabetes met with high hurdles. We must treat these patients in thinking about osteocytic perilacunar/canalicular system.
DOI CliCa1606875880
PMID 27230843